Tumors exhibit altered tissue-level and cell mechanics, including extracellular matrix (ECM) remodeling and stiffening, elevated interstitial pressure and altered mass transport 1 . Experimental models demonstrate that enhancing ECM stiffness promotes malignancy and, conversely, inhibiting matrix stiffening reduces tumor incidence and improves treatment [2] [3] [4] . Nevertheless, the molecular mechanisms by which mechanics influence cell behavior to modulate malignancy are poorly understood. Additionally, the clinical consequences of altered biophysical cues in the onset, histopathology and progression of cancer remain unclear.
Tumors exhibit altered tissue-level and cell mechanics, including extracellular matrix (ECM) remodeling and stiffening, elevated interstitial pressure and altered mass transport 1 . Experimental models demonstrate that enhancing ECM stiffness promotes malignancy and, conversely, inhibiting matrix stiffening reduces tumor incidence and improves treatment [2] [3] [4] . Nevertheless, the molecular mechanisms by which mechanics influence cell behavior to modulate malignancy are poorly understood. Additionally, the clinical consequences of altered biophysical cues in the onset, histopathology and progression of cancer remain unclear.
MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression that are altered in multiple cancers, where they modulate levels of tumor suppressors and oncogenes that regulate cell growth, survival and invasion 5, 6 . miRNAs also regulate cell-cell and cell-matrix interactions, including integrin-dependent adhesion 7 . Integrin signaling is increased in tumors and reduced when ECM stiffening is prevented, indicating potential functional links between miRNAs and tumor mechanics 2, 3 . Indeed, ECM stiffness potentiates transforming growth factor-β-induced miRNA-dependent metastasis of malignant mammary epithelial cells (MECs) 8 , and shear stress and cyclic stretch induce miRNAs in alveolar epithelial and endothelial cells 9, 10 . These results indicate that miRNAs are sensitive to mechanical cues.
At the intersection of many pathways involved in malignant transformation is phosphoinositide 3-kinase (PI3K), which is critical for cell growth, survival and invasion 11 . We showed previously that ECM stiffness directly modulates ErbB receptor-dependent PI3K activation and MEC invasion and that PI3K signaling is reduced by inhibiting ECM stiffening in vivo 2, 3 , which implies that molecules that influence PI3K signaling are mechanically regulated. As a key negative regulator of PI3K activity, PTEN is a tumor suppressor whose expression is frequently reduced in human cancers 12, 13 . Here, we used global profiling to identify a mechanically regulated miRNA, miR-18a, that targets PTEN, both directly and indirectly by decreasing levels of HOXA9, to promote PI3K-dependent malignancy. Clinically, miR-18a expression predicted clinical outcome in patients with luminal breast cancers.
RESULTS

ECM stiffness modulates miRNA expression
To identify molecular mechanisms whereby mammary tissue responds to differences in the mechanical microenvironment, we profiled miRNAs expressed in nonmalignant MCF-10A human MECs (hMECs) on soft (<400 Pa) or stiff (>5 kPa) polyacrylamide (PA) gels conjugated with recombinant basement membrane ( Fig. 1a and Supplementary Tables 1 and 2) . Interrogation of differentially expressed miRNAs showed changes in levels of total and mature miRNAs in response to stiffness and revealed that unprocessed miRNAs were somewhat disproportionately upregulated by ECM stiffness (two-sided Kolmogorov-Smirnov test, P = 0.040, Supplementary  Fig. 1a) . In vivo, in the polyoma middle T (PyMT) mouse model of breast cancer, we also observed that miRNAs were similarly regulated by ECM stiffness when we prevented ECM cross-linking and stiffening in mammary tumors by treating mice either with the lysyl oxidase (LOX) pharmacological inhibitor β-aminopropionitrile or with a specific function-blocking antibody to LOX; these results indicate that cellular miRNAs are responsive to matrix mechanics ( Fig. 1b and 
Supplementary Tables 3 and 4).
We noted that within the pool of differentially expressed mature miRNAs in the hMECs cultured on the stiff PA gels, miRNAs belonging to the polycistronic miR-17-92 cluster were consistently induced (Supplementary Table 1 ). As the miR-17-92 cluster has been implicated in malignancy 14, 15 , we explored the impact of this cluster on stiffness-mediated malignant transformation. Dysregulated expression of the cluster's individual miRNAs can drive malignancy through an imbalance of proliferation, apoptosis and differentiation 15, 16 . Notably, only one specific cluster member, miR-18a, had significantly and consistently increased expression in response to ECM stiffness (Fig. 1c) . Indeed, whereas the miR-17-92 cluster was upregulated with mouse mammary gland transformation, only miR-18a was significantly inhibited in PyMT tumors when tissue fibrosis and stiffening were reduced through LOX inhibition ( Fig. 1d and Supplementary   Fig. 2a-c) . As we were interested in identifying stiffness-regulated tumor suppressor pathways, we focused our efforts on delineating the role of miR-18a in the mechanical regulation of malignancy.
We first determined that substrate mechanics robustly and consistently increased miR-18a levels in several nonmalignant and transformed breast cancer cell lines 17 in culture ( Supplementary  Fig. 1b) . We then confirmed that miR-18a induced no detectable changes in cell proliferation or apoptosis but did increase anchorageindependent colony formation in MCF-10A, MCF-7 and T4-2 breast cancer cells (Supplementary Fig. 1c,d) . Orthotopic experiments conducted using PyMT mammary tumor cells injected into the cleared mammary fat pads of FVB mouse hosts revealed that increasing miR-18a levels enhanced growth and final tumor volume, as well as lung metastasis (Fig. 1e,f) . We also found that antisense miRNA (antagomir)-mediated knockdown of miR-18a (ref. 18 ) in MCF-7 and T4-2 cells compromised their growth and survival in soft agar culture (Supplementary Fig. 1e ). Indeed, knockdown of miR-18a reduced growth and final tumor volume of PyMT mammary tumor cells injected into the cleared fat pad of FVB mice (Fig. 1g) and inhibited their ability to form lung metastasis in a tail vein assay ( Fig. 1h and Supplementary Fig. 1f ). These findings identify miR-18a as a mechanically regulated tumor enhancer.
ECM stiffness induces miR-18a to reduce PTEN levels We identified putative binding regions [19] [20] [21] [22] for miR-18a in the 3′ untranslated region (UTR) of the tumor suppressor PTEN PyMT orthotopic final volume a n t -C T L a n t -1 8 a npg ( Supplementary Fig. 3a ). Reporter assays 23 using the putative wild-type (WT) and mutated 3′ UTRs of PTEN confirmed that miR-18a interacts with and inhibits PTEN transcription at two of three predicted sites ( Fig. 2a and Supplementary Fig. 3b ). PTEN mRNA expression was reduced in hMECs grown on a stiff substrate (Fig. 2b) . Immunofluorescence and immunoblotting also demonstrated loss of PTEN expression in hMECs grown on a stiff substrate, with markedly reduced expression in both the nuclear and cytoplasmic fractions (Fig. 2c,d ). PTEN mRNA expression was similarly reduced in stiff mouse mammary tumor tissue, and inhibiting stromal stiffening prevented PTEN loss ( Fig. 2e and Supplementary Fig. 2d ). Finally, we documented an inverse correlation between PI3K activity, indicated by elevated levels of phosphorylated Akt on Ser473 (pS473-Akt), and PTEN protein, without any change in cell proliferation or apoptosis, which suggests that ECM stiffness could induce miR-18a to modulate malignant progression of the mammary gland by regulating PTEN (Fig. 2f and Supplementary Fig. 2e-g ).
To directly implicate miR-18a in PTEN modulation, we tested whether antagomir-mediated knockdown of miR-18a could restore PTEN levels in hMECs grown on a stiff ECM. hMECs expressing an antagomir to miR-18a retained PTEN expression even when grown on a stiff PA gel, in contrast to the modest increase observed in hMECs expressing an antagomir to miR-19b (Fig. 2g) . PTEN levels were reduced when miR-18a was ectopically expressed in hMECs cultured on a soft ECM (Fig. 2h) . Notably, PTEN mRNA expression was increased in PyMT tumors in which miR-18a levels had been reduced, and we noted a reduction in PTEN mRNA expression in PyMT tumors in which miR-18a levels had been increased (Fig. 2i,j ). These findings demonstrate that ECM stiffness represses PTEN and promotes PI3K-dependent malignant progression of the mammary gland by increasing miR-18a levels.
ECM stiffness induces miR-18a to reduce HOXA9 levels miRNAs typically have multiple targets, and miRNA target prediction software [19] [20] [21] [22] also identified a putative binding region for miR-18a in the 3′ UTR of the homeobox transcription regulator HOXA9 ( Supplementary  Fig. 3a) . We previously reported that HOXA9 restricts the malignant behavior of breast cancer cells in vitro and in vivo and that HOXA9 levels are reduced in human breast cancers and predict poor patient outcome 24 . Accordingly, we explored the impact of miR-18a on HOXA9.
Reporter assays using a 3′ UTR of HOXA9 containing the putative miR-18a binding region confirmed that miR-18a interacts with and β-actin a n t -1 9 b a n t -C T L a n t -1 8 a a n t -C T L a n t -1 8 a Relative 3′ UTR activity 
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Nuclear Cytoplasmic pH H3 a n t -1 9 b a n t -C T L a n t -1 8 a a n t -C T L a n t -1 8 a a n t -C T L a n t -1 8 a npg inhibits HOXA9 expression and showed that mutating this domain ablates this regulation (Fig. 3a) . Immunoblotting demonstrated significant loss of HOXA9 protein expression in hMECs grown on a stiff substrate, with no change in HOXA9 mRNA levels (Fig. 3b,c) . Immunofluorescence analysis showed robust co-staining of HOXA9 and PTEN only in hMECs grown on soft ECM and a concomitant loss of both proteins when hMECs were grown on a stiff ECM (Fig. 3d) . Moreover, immunofluorescence staining of mammary tissues detected high levels of Hoxa9 in normal mouse mammary tissue and showed that, whereas this expression was lost in the stiffened mammary tumor tissue, inhibiting tissue stiffness tempered the loss of Hoxa9, with little effect on mRNA expression (Fig. 3e,f and Supplementary  Fig. 2d,e) . These data suggest that miR-18a could also regulate mammary malignancy by regulating HOXA9.
To directly implicate miR-18a in HOXA9 modulation, we tested whether antagomir-mediated knockdown of miR-18a could restore HOXA9 levels in hMECs grown on a stiff ECM. hMECs expressing an antagomir to miR-18a retained HOXA9 expression even when grown on a stiff PA gel (Fig. 3g) . Moreover, HOXA9 levels were reduced when miR-18a was ectopically elevated in hMECs cultured on a soft ECM (Fig. 3h) . We also observed an increase in Hoxa9 mRNA expression in PyMT tumors in which miR-18a had been knocked down and PTEN was restored, as well as a reduction in Hoxa9 mRNA expression in PyMT tumors in which miR-18a abundance had been increased and PTEN levels reduced (Fig. 3i,j) . These findings imply a coordinate regulation of HOXA9 and PTEN by miR-18a, suggesting that ECM stiffness promotes malignancy by inducing miR-18a to reduce expression of HOXA9 and PTEN.
ECM stiffness prevents HOXA9-dependent PTEN transcription Our previously published microarray results suggested that HOXA9 induces PTEN expression in breast cancer cells 24 . Consistent with this predicted link between HOXA9 and PTEN, we noted that shRNAmediated reduction of HOXA9 levels resulted in a significant loss of PTEN mRNA, even when nonmalignant hMECs were grown on a soft ECM where PTEN levels are elevated (Fig. 4a) . Furthermore, increasing levels of HOXA9 using an expression plasmid lacking the HOXA9 3′ UTR restored PTEN levels in nonmalignant hMECs grown on a stiff ECM and increased PTEN mRNA levels in two breast cancer cell lines (Fig. 4b,c) . Moreover, ectopic expression of Hoxa9 in PyMT tumor cells orthotopically injected into FVB mice increased Pten mRNA expression and reduced growth and final tumor volume without affecting miR-18a levels (Fig. 4d-f) . These findings indicate that HOXA9 modulates mammary tumorigenesis by regulating PTEN.
Reporter assays using the proximal promoter region of PTEN 25, 26 , which contains homeobox consensus binding sites, confirmed that luciferase activity was enhanced after transfection with increasing amounts of a plasmid encoding WT HOXA9 but not after transfection with a DNA-binding domain-mutant HOXA9 (N255T; DNA BM) or with HOXA10 (Fig. 4g,h ). These assays also confirmed that HOXA9 induces PTEN expression independent of the HOX cofactors PBX1 and MEIS1 (Fig. 4i) . Chromatin immunoprecipitation (ChIP) studies conducted using endogenous HOXA9 as the bait (in MECs grown on soft ECMs where they express high levels of HOXA9 protein) confirmed that HOXA9 directly binds to the PTEN promoter (Fig. 4j) . This effect was markedly decreased when HOXA9 levels were reduced β-actin a n t -C T L a n t -1 8 a a n t -C T L a n t -1 9 b a n t -1 8 a Stiff Soft a n t -C T L a n t -1 8 a a n t -C T L a n t -1 9 b a n t -1 8 a via shRNA (Fig. 4j) . These findings indicate that HOXA9 directly binds to the PTEN promoter to regulate its expression and inhibit malignancy of breast cells. These results also demonstrate that increasing mechanical stiffness represses PTEN expression both directly via miR-18a targeting and indirectly via miR-18a targeting of HOXA9.
Tissue stiffness engages mechanotransduction signaling miRNAs exhibit differential expression across breast cancer subtypes 27 , with both tumor initiation and progression regulated by MYC proto-oncogene stimulation of the miR-17-92 cluster 28 . We therefore hypothesized that MYC-driven miRNA expression could be distinctly controlled by the mechanical microenvironment. Both mRNA and protein levels of MYC increased with substrate stiffness for nonmalignant and malignant hMECs ( Fig. 5a and Supplementary Fig. 4a ). Pharmacological inhibition of MYC in hMECs cultured on a stiff substrate reduced miR-18a levels (Fig. 5b) , suggesting a functional link between MYC expression and mechanics. Myc mRNA expression was increased in mouse mammary tumors compared to WT glands, and LOX inhibition reduced both mRNA and protein expression relative to untreated tumors (Supplementary Fig. 4b) , despite similar levels of cell proliferation (Supplementary Figs. 1c and 2f,g ). These results suggest that MYC is upregulated by increasing matrix stiffness in culture and in vivo, at both the mRNA and protein levels.
Previous work established MYC as a downstream target of β-catenin signaling 29 . Nuclear β-catenin levels were increased in hMECs grown on stiff substrates (Supplementary Fig. 4c) , and the ratio of activated to total β-catenin protein increased with substrate stiffness ( Fig. 5c and Supplementary Fig. 4c ). Immunofluorescence also revealed that ECM stiffness increased total nuclear β-catenin (Fig. 5c) . Moreover, nuclear localization of total β-catenin and β-catenin activation were reduced in glands with LOX-inhibited relative to control PyMT tumors (Supplementary Fig. 4d,e) .
In both the culture and in vivo models, β-catenin mRNA levels were unchanged by ECM stiffness (Supplementary Fig. 4f) . However, Y397-FAK phosphorylation (indicating FAK activation), glycogen synthase kinase-3α (GSK-3α) and GSK-3β (GSK-3α/β) phosphorylation (indicating GSK-3 inactivation) and S473-Akt phosphorylation (indicating Akt activity) increased with stiffness, suggesting that integrin-dependent signaling activates β-catenin ( Fig. 5d and Supplementary Figs. 2g and 5a,b) . Inhibiting FAK reduced miR-18a expression and increased HOXA9 and PTEN protein expression (Fig. 5e) . Additionally, inhibition of miR-18a reduced both Akt and GSK-3α/β phosphorylation in hMECs cultured on stiff substrates (Supplementary Fig. 5c,d ). These data demonstrate that tissue stiffening modulates miRNA-dependent PTEN expression through integrin-dependent activation of β-catenin and MYC.
To facilitate integrin clustering in vivo, transgenic mice expressing a conditional V737N β 1 integrin clustering mutant, which recapitulates tension-dependent integrin clustering and promotes focal adhesion signaling 2 , were bred with transgenic mouse line expressing MMTVCre (Cre under control of mouse mammary tumor virus promoter) to promote mammary gland-specific expression. Consistent with enhancement of focal adhesion assembly and signaling, Y397-FAK phosphorylation increased in the V737N mutant glands (Fig. 5f) . npg β-catenin nuclear localization was also increased in the epithelium of the V737N mammary glands (Fig. 5g) , as were Myc mRNA and miR-18a levels (Fig. 5h) . Notably, Hoxa9 mRNA and protein expressions were inversely correlated with miR-18a in normal and V737N mutant mammary glands ( Fig. 5i and Supplementary Fig. 5e ). Finally, Pten mRNA and protein expression levels were reduced in the V737N mammary glands compared to in WT controls ( Fig. 5i and Supplementary Fig. 5f ). These results indicate that the mechanical microenvironment influences PTEN expression downstream of integrin activation of β-catenin signaling.
Breast malignancy associates with increased miR-18a
We investigated the clinical relevance of ECM stiffness-induced miR-18a upregulation and PTEN repression by assessing the RNA and protein expression of HOXA9 and PTEN in cohorts of clinically diverse human breast cancers and normal tissue. miR-18a expression was notably higher in samples from patients with breast cancer than in nonmalignant samples, with expression in either basal-like or luminal B samples significantly higher than the expression in either the normal or luminal A samples (Fig. 6a) . As measured by atomic force microscopy, miR-18a expression correlated with breast ECM stiffness in both normal and transformed breast tissue (R 2 = 0.7197, P < 0.001, Fig. 6b) , with luminal B samples stiffer than luminal A samples (Fig. 6c) . PTEN and HOXA9 mRNA expressions were reduced in luminal B cancers compared to normal breast tissue, and further reduced in basal-like cancers (Fig. 6d) . Indeed, HOXA9 correlated with PTEN in normal and transformed breast tissue for both mRNA (R 2 = 0.8979) and protein expressions, consistent with our findings that PTEN is regulated by HOXA9 (Fig. 6e,f) . The epithelium of normal breast tissue coexpressed appreciable quantities of nuclear HOXA9 and cytoplasmic PTEN proteins, as did the more differentiated luminal A breast tumors (Fig. 6f) . In contrast, the less differentiated luminal B, basal-like and HER2 + tumors showed reduced expression of HOXA9 and PTEN and higher levels of activated AKT (pAKT substrate), phospho-S6 and inactivated pGSK-3 ( Fig. 6f and Supplementary Fig. 6a ). These clinical findings, together with our experimental data, are consistent with the notion that miR-18a and HOXA9 modulate PTEN expression by cooperating with multiple negative and positive regulatory factors differentially expressed in human breast tumors 13 . We next analyzed publicly available gene expression data sets to look for associations between miR-18a and clinical outcome 30, 31 . In patient samples without mutations in PTEN, we found that the expression of PTEN correlated with miR-18a expression, but only if HOXA9 was unmethylated (P < 0.0001, Supplementary Fig. 6b) . We found that miR-18a expression inversely correlated with time to distant relapsefree survival (DRFS) in patients whose tumors expressed the highest miR-18a levels at initial diagnosis (highest quartile) and experienced npg distant metastases as a second event, regardless of subtype (P = 0.0173, Supplementary Fig. 6c ). Including multiple PTEN-targeting miRNAs in two different models, we found that miR-18a expression levels were predictive of outcome among patients with luminal breast cancers (P = 0.017 and P = 0.049, Fig. 6g and Supplementary Fig. 6d ). These data indicate that miR-18a is upregulated in basal-like breast cancers and its expression correlates with increased future disease aggression for patients with luminal breast cancers. Combined, these findings identify a mechanically regulated molecular circuit that may promote malignancy and suggest that matrix stiffness could influence breast cancer pathogenesis (Fig. 6h) .
DISCUSSION Here, we demonstrate that miRNA expression is responsive to ECM stiffness. We present in vitro and in vivo evidence to show that one miRNA, miR-18a, mediates stiffness-dependent malignancy of breast epithelium. By demonstrating that elevated ECM stiffness engages a miR-18a circuit that promotes PI3K-dependent malignant progression by targeting the tumor suppressor PTEN directly and indirectly via tumor modifier HOXA9, we established miRNAs as key mediators of tumor mechanics. Given that tissue mechanics are often altered in tumors, our findings provide a plausible explanation for the frequent alteration of miRNA expression across multiple cancer types 6 . Indeed, integrin adhesions and ion channel activity are central players in mechanotransduction that are altered in malignancy and regulated by miRNAs 7, 32, 33 . Notably, ECM stiffness is one of multiple aspects of tissue mechanics, which also compromises tissue architecture, interstitial pressure and mass transport; these physical cues also influence miRNA expression, thereby reinforcing the concept that miRNAs are part of a force-regulated signaling network 1, [34] [35] [36] . Ultrasound and shear wave elastography interrogate tissue stiffness as a screening procedure to detect cancer [37] [38] [39] . Yet, studies in experimental models argue that tissue mechanics have more than just a passenger role in tumor progression 2, 3, 34 . In patient biopsies, our data indicate that miR-18a levels can distinguish luminal A from luminal B tumors and predict clinical outcome in patients with luminal type breast cancer. Our studies are consistent with elastography data on patients with breast cancer, suggesting that macro-level tumor stiffness may parallel aggression, with tumor size, grade and subtype as independent factors influencing tissue mechanics [38] [39] [40] . We extend these observations to show that ECM stiffness can engage a specific molecular pathway, miR-18a regulation of PTEN and HOXA9, that could be clinically exploited. In this regard, luminal breast cancers vary heterogeneously in terms of gene expression, mutations, copy npg number changes and patient outcome and present a major challenge to identify patients with aggressive versus indolent tumors 31, 41, 42 . Our work identifies ECM stiffness as a biophysical parameter that can distinguish luminal A from luminal B tumors with miR-18a, PTEN and HOXA9 presenting as tractable biomarkers.
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